FULC News and Press, Fulcrum Therapeutics Inc.

2026-02-26 11:10:49 ET Overview I’ve covered Fulcrum ( FULC ) a couple of times in the past. It has a new look today. In 2023, Fulcrum was evaluating losmapimod in a registrational-enabling study in Facioscapulohumeral Muscular Dystrophy. I was not very confident ahead of...

2026-02-24 15:28:01 ET Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call February 24, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript

2026-02-24 14:03:47 ET Gregory Renza from Truist Financial issued a price target of $17.00 for FULC on 2026-02-24 18:38:20. The adjusted price target was set to $17.00. At the time of the announcement, FULC was trading at $8.955. The overall price target consensus is at ...

2026-02-24 11:30:03 ET H.C. Wainwright analyst issues BUY recommendation for FULC on February 24, 2026 04:51PM ET. The previous analyst recommendation was Buy. FULC was trading at $9.218 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...

2026-02-24 07:20:00 ET More on Fulcrum Therapeutics Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cel...

― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a basel...

― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (...

Interface Inc. (TILE) is expected to report $0.4 for Q4 2025 Evolent Health Inc Class A (EVH) is expected to report $-0.03 for Q4 2025 MercadoLibre Inc. (MELI) is expected to report $11.77 for Q4 2025 Clean Energy Fuels Corp. (CLNE) is expected to report $-0.1 for Q4 2025 Kiniksa ...

CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call an...

2026-01-14 14:46:01 ET Fulcrum Therapeutics, Inc. (FULC) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 1:30 PM EST... Read the full article on Seeking Alpha For further details see: Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Health...